Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread.
作者信息
Graham David Y, Lu Hong
出版信息
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):1-2. doi: 10.4103/1319-3767.91724.
Abstract
摘要
相似文献
1
Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread.呋喃唑酮在幽门螺杆菌治疗中的应用：一个法式面包的故事讲述了一种被误解且常遭不公正诋毁的药物。
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):1-2. doi: 10.4103/1319-3767.91724.
2
Furazolidone therapy for Helicobacter pylori: is it effective and safe?呋喃唑酮治疗幽门螺杆菌：它有效且安全吗？
World J Gastroenterol. 2009 Apr 21;15(15):1914-5. doi: 10.3748/wjg.15.1914.
3
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for infection and predictors of failed eradication.呋喃唑酮和阿莫西林四联疗法治疗感染的结果及根除失败的预测因素。
World J Gastroenterol. 2018 Oct 28;24(40):4596-4605. doi: 10.3748/wjg.v24.i40.4596.
4
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.含呋喃唑酮的短期三联疗法对幽门螺杆菌感染的治疗有效。
Aliment Pharmacol Ther. 1999 Mar;13(3):317-22. doi: 10.1046/j.1365-2036.1999.00492.x.
5
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.使用枸橼酸铋钾、呋喃唑酮和克拉霉素三联疗法治疗幽门螺杆菌感染1周，治愈率高。
Aliment Pharmacol Ther. 1999 Mar;13(3):311-5. doi: 10.1046/j.1365-2036.1999.00487.x.
6
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.在基于甲硝唑的治疗方案失败的患者中，采用基于呋喃唑酮的方案进行二线幽门螺杆菌根除治疗。
Digestion. 2001;64(4):222-5. doi: 10.1159/000048865.
7
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.幽门螺杆菌标准三联疗法根除失败后采用一周的奥美拉唑、呋喃唑酮和阿莫西林补救治疗。
Aliment Pharmacol Ther. 2002 Apr;16(4):793-8. doi: 10.1046/j.1365-2036.2002.01223.x.
8
A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease.一种基于呋喃唑酮的四联疗法用于消化性溃疡疾病患者幽门螺杆菌再治疗。
Clinics (Sao Paulo). 2005 Dec;60(6):485-8. doi: 10.1590/s1807-59322005000600010. Epub 2005 Dec 12.
9
Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.基于呋喃唑酮的幽门螺杆菌感染治疗：汇总数据分析。
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):11-7. doi: 10.4103/1319-3767.91729.
10
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.含枸橼酸铋雷尼替丁、呋喃唑酮及阿莫西林或四环素的一周治疗方案能有效根除幽门螺杆菌：一项多中心、随机、双盲研究。
Aliment Pharmacol Ther. 2001 Dec;15(12):1975-9. doi: 10.1046/j.1365-2036.2001.01122.x.
引用本文的文献
1
Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.改良铋剂四联疗法一线根除幽门螺杆菌的疗效与安全性：一项随机对照试验的系统评价和Meta分析
Microorganisms. 2025 Feb 26;13(3):519. doi: 10.3390/microorganisms13030519.
2
Implications of the paradigm shift in management of infections.感染管理模式转变的影响
Therap Adv Gastroenterol. 2023 Mar 18;16:17562848231160858. doi: 10.1177/17562848231160858. eCollection 2023.
3
Short-term outcomes and intermediate-term follow-up of infection treatment for naïve patients: a retrospective observational study.初治患者感染治疗的短期结局和中期随访：一项回顾性观察研究。
BMJ Open. 2022 Sep 17;12(9):e062096. doi: 10.1136/bmjopen-2022-062096.
4
Current guidelines for treatment in East Asia 2022: Differences among China, Japan, and South Korea.《2022年东亚治疗指南：中国、日本和韩国之间的差异》
World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349.
5
Susceptibility-guided bismuth quadruple therapies for resistant infections.药敏指导下的铋剂四联疗法治疗耐药感染。
Precis Clin Med. 2020 Jun;3(2):127-135. doi: 10.1093/pcmedi/pbaa010. Epub 2020 Mar 17.
6
Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant infection.对至少经历五次根除治疗失败且感染多重耐药的患者使用呋喃唑酮进行挽救治疗。
Antibiotics (Basel). 2021 Aug 24;10(9):1028. doi: 10.3390/antibiotics10091028.
7
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.幽门螺杆菌感染和抗生素耐药性 - 从生物学到临床意义。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. doi: 10.1038/s41575-021-00449-x. Epub 2021 May 17.
8
Safety of furazolidone-containing regimen in infection: a systematic review and meta-analysis.呋喃唑酮方案治疗感染的安全性：系统评价和荟萃分析。
BMJ Open. 2020 Oct 19;10(10):e037375. doi: 10.1136/bmjopen-2020-037375.
9
Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for eradication: A prospective open-label randomized trial.两周铋剂四联疗法与伴随疗法作为一线方案根除幽门螺杆菌：一项前瞻性、开放标签、随机试验。
World J Gastroenterol. 2019 Dec 14;25(46):6790-6798. doi: 10.3748/wjg.v25.i46.6790.
10
Effective therapeutic regimens in two South Asian countries with high resistance to major antibiotics.在两个对抗生素高度耐药的南亚国家中有效的治疗方案。
Antimicrob Resist Infect Control. 2019 Feb 15;8:40. doi: 10.1186/s13756-019-0482-x. eCollection 2019.
本文引用的文献
1
Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.基于呋喃唑酮的幽门螺杆菌感染治疗：汇总数据分析。
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):11-7. doi: 10.4103/1319-3767.91729.
2
Helicobacter pylori therapy demystified.幽门螺杆菌治疗揭秘。
Helicobacter. 2011 Oct;16(5):343-5. doi: 10.1111/j.1523-5378.2011.00891.x.
3
Understanding and appreciating sequential therapy for Helicobacter pylori eradication.理解和欣赏幽门螺杆菌根除的序贯疗法。
J Clin Gastroenterol. 2011 Apr;45(4):309-13. doi: 10.1097/MCG.0b013e31820ac05e.
4
Optimal therapy for Helicobacter pylori infections.幽门螺杆菌感染的最佳治疗方法。
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):79-88. doi: 10.1038/nrgastro.2010.210.
5
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.幽门螺杆菌感染根除治疗的药理学方面。
Gastroenterol Clin North Am. 2010 Sep;39(3):465-80. doi: 10.1016/j.gtc.2010.08.007.
6
Helicobacter pylori treatment in the era of increasing antibiotic resistance.幽门螺杆菌在抗生素耐药时代的治疗。
Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4.
7
Efficient identification and evaluation of effective Helicobacter pylori therapies.有效鉴定和评估幽门螺杆菌的有效治疗方法。
Clin Gastroenterol Hepatol. 2009 Feb;7(2):145-8. doi: 10.1016/j.cgh.2008.10.024. Epub 2008 Oct 30.
8
Some food additives, feed additives and naturally occurring substances.一些食品添加剂、饲料添加剂和天然存在的物质。
IARC Monogr Eval Carcinog Risk Chem Hum. 1983 Jul;31:1-291.
9
In vivo susceptibility of Campylobacter pylori.幽门螺杆菌的体内易感性。
Am J Gastroenterol. 1989 Mar;84(3):233-8.
Zotero 插件